Analyst Price Targets — GOVX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 2, 2024 6:42 am | Vernon Bernardino | H.C. Wainwright | $100.00 | $41.00 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on GeoVax Labs Inc. (GOVX) |
Latest News for GOVX
GeoVax Labs (GOVX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
GeoVax Labs, Inc. (GOVX) Discusses Building a Resilient Infectious Disease Preparedness Strategy Focused on Ebola, Marburg, Hantavirus, and Mpox Transcript
GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotech company, is trading higher on Wednesday as investors assess the company's recent financing deal alongside growing attention on its vaccine platform developments.
GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GOVX.
U.S. House Trading
No House trades found for GOVX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.